Hatice Bölek

Ankara University — Turkey

Medicine · Health Sciences

6h-index127citations59works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(16), Cancer Immunotherapy and Biomarkers(11), Prostate Cancer Treatment and Research(8), Pancreatic and Hepatic Oncology Research(6), Bladder and Urothelial Cancer Treatments(6)

Publications59 total

Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
Scientific Reports·2026Open Access
Outcomes and prognostic markers in locally advanced head and neck squamous cell carcinoma underwent chemoradiotherapy
Discover Oncology·2025Open Access
Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer
Cancer Investigation·2025
Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials
The Oncologist·2025· 1 citedOpen Access
Sequential use of targeted radioligand therapies in metastatic castration-resistant prostate cancer: A case report and systematic review
Critical Reviews in Oncology/Hematology·2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Cancer Immunology Immunotherapy·2025Open Access
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study
JCO Global Oncology·2025Open Access
Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma
BMC Cancer·2025Open Access
Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration‐Sensitive Prostate Cancer
The Prostate·2025
Confirmation of Large Language Models in Head and Neck Cancer Staging
Diagnostics·2025Open Access
A retrospective multicenter study on solitary fibrous tumors: investigation of clinical features and management approaches
Journal of Health Sciences and Medicine·2025Open Access
3060eP Immunomodulatory effect of cisplatin versus carboplatin on tumor microenvironment and anti-PD-1 response: A multicenter real-world analysis
Annals of Oncology·2025
Re: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
ESMO Open·2025Open Access
2681eP Real-world comparison of immunotherapy (IO)-based combinations in intermediate/poor-(int/poor-) risk patients (pts) with non-clear cell Renal Cell Carcinoma (nccRCC): The ARON-1 multicenter experience
Annals of Oncology·2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)
Cancers·2025Open Access
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)
Journal of Clinical Medicine·2025Open Access
Soliter fibröz tümörler üzerine retrospektif çok merkezli bir çalışma: klinik özellikler ve tedavi yaklaşımlarının incelenmesi
DergiPark (Istanbul University)·2025
Re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623–31
European Urology Oncology·2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
European Urology Focus·2025· 1 cited
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma
BMC Cancer·2025· 1 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Yüksel Ürün(28), Emre Yekedüz(17), Mehmet Alı Nahıt Şendur(9), Çağatay Arslan(8), Selver Işık(7), Deniz Tural(7), Nuri Karadurmuş(7), Cengiz Karaçin(7), Satı Coşkun Yazgan(6), Omer F. Kuzu(6), Sung Hoon Sim(6), Serhat Sekmek(6), Özlem Nuray Sever(6), Tülay Kuş(6), Abdullah Akkuş(5), Furkan Ceylan(5), Ömer Küçük(5), Deniz Tural(5), Elif Sertesen Çamöz(4), Sema Sezgin Göksu(4)